Mar 2015 $17 M No. 3 $10 to $50 million 14
Cynapsus Therapeutics Inc.: Raise no. 3, Mar 2015 × Investors in this round 14 investors had bought by the notice of Apr 14, 2015: 14 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $17 M of $17 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions $1,005,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Canada (Federal Level) People named in the notice Andrew Williams · Executive Officer Anthony Giovinazzo · Executive Officer, Director Thierry D. Bilbault · Executive Officer Ilan Nan Oren · Director Margaret Nan Hutchinson · Director Perry Nan Molinoff · Director Rochelle D. Stenzler · Director Ronald Hosking · Director Tamar D. Howson · Director Tomer Gold · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Noble Financial Capital Markets (CRD 15768) · Boca Raton, Florida Sold in CA, NY Signed by Andrew Williams, Chief Operating Officer and Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 14, 2015. Read the notice at the SEC .
equity SEC Apr 2014 $15 M No. 2 $10 to $50 million 19
Cynapsus Therapeutics Inc.: Raise no. 2, Apr 2014 × Investors in this round 19 investors had bought by the notice of Apr 21, 2014: 19 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $15 M of $43 M offered; $28 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Each unit is comprised of one common share and one share purchase warrant. Each warrant is exercisable for one common share at an exercise price of Cdn$0.81 for a period of 60 months. Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue No revenue
Sales commissions $1,018,240
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Canada (Federal Level) People named in the notice Andrew Williams · Executive Officer Anthony Giovinazzo · Executive Officer, Director Alan D. C. Ryley · Director Ilan Oren · Director Nan Hutchinson · Director Perry Molinoff · Director Rochelle D. C. Stenzler · Director Ronald Hosking · Director Tomer Gold · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Maddie King III (CRD 2784584) · broker-dealer Brookline Group, LLC (CRD 153587) · Birmingham, Alabama Sold in CA, FL, IL, NY Noble Financial Capital Markets (CRD 15768) · Boca Raton, Florida Sold in CA, FL, IL, NY Remarks in the notice On fees: “The agent also received warrants exercisable for approximately 1,720,199 shares of common stock of the issuer at a price of Cdn$0.81 per share for a period of 60 months with respect to the U.S. portion of the offering.”On the amounts: “The additional $28,370,682 may be received upon the exercise of share purchase warrants sold inside and outside the U.S. U.S. dollar amounts are based on the Bank of Canada noon rate of exchage report on April 15, 2014, which was CN$1.0981=US$1.00.”On the use of proceeds: “In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.”Signed by Andrew Williams, Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 21, 2014. Read the notice at the SEC .
equity, options SEC Mar 2013 $4 M No. 1 $2 to $10 million 5
Cynapsus Therapeutics Inc.: Raise no. 1, Mar 2013 × Investors in this round 5 investors had bought by the notice of Mar 27, 2013: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $13 M offered; $9 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Each unit it comprised of one common share and one common share purchase warrant. Each warrant is exercisable for one common share at an exercise price of Cdn$0.575 per share for a period of 60 months
Meant to last more than a year
Issuer's revenue No revenue
Sales commissions $101,664
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Ontario, Canada People named in the notice Andrew Williams · Executive Officer Anthony Giovinazzo · Executive Officer, Director Nathan Bryson · Executive Officer Alan D. C. Ryley · Director Alan D. C. Torrie · Director Julia Levy · Director Perry Molinoff · Director Rochelle D. C. Stenzler · Director Ronald Hosking · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Moody Capital Solutions, Inc. (CRD 15989) · broker-dealer M Partners Inc. · Dawsonville, Georgia Sold in CA Brookline Group, LLC (CRD 153587) · broker-dealer M Partners Inc. · Birmingham, Alabama Sold in AL Remarks in the notice On fees: “The underwriters also received broker warrants exercisable for approximately 1,962,087 shares of common stock of the issuer at a price of Cdn$0.575 per share for a period of 60 months with respect to the U.S. portion of the offering.”On the amounts: “The additional $8,893,457 may be received upon exercise of share purchase warrants sold both inside and outside the U.S. U.S. dollar amounts are based on the Bank of Canada noon rate of exchange reported on March 1, 2013, which was Cdn$1.0285=US$1.00.”On the use of proceeds: “In the ordinary course of business, the issuer may use some of the proceeds to pay salaries to certain of its executive officers and directors.”Signed by Andrew Williams, Chief Financial Officer and Chief Operations Officer. Source: SEC Form D and 1 amendment, newest notice filed Mar 27, 2013. Read the notice at the SEC .
equity, options SEC